RG-6007

N/A

Report date: 2026/03/19 17:22:29

Base Information

Drug NameRG-6007

Drug Alias NameRG-6007RO-7283420

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD3Wilms' Tumour 1 modulators

TargetsT cell surface glycoprotein CD3Wilms' Tumour 1

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesTaiwan +[10]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesF. Hoffmann-La Roche Ltd

China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche Ltd

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A